Lasea (Silexan): Uses, Dosage & Side Effects
Standardized lavender oil capsules for the treatment of anxiety and restlessness
Lasea is a herbal medicine containing Silexan, a patented standardized essential oil preparation from Lavandula angustifolia (narrow-leaved lavender). It is used to treat anxiety disorders, subsyndromal anxiety, and restlessness in adults. Multiple randomized controlled trials have demonstrated that Silexan 80 mg daily is as effective as lorazepam 0.5 mg daily for generalized anxiety disorder, without the risks of sedation, dependence, or withdrawal. Lasea is approved in over 15 countries and is one of the most extensively studied herbal anxiolytics available.
Quick Facts
Key Takeaways
- Lasea contains Silexan, a standardized lavender oil extract clinically proven to reduce anxiety symptoms comparable to lorazepam 0.5 mg
- Unlike benzodiazepines, Lasea does not cause sedation, cognitive impairment, dependence, or withdrawal symptoms
- The standard dosage is one 80 mg soft capsule taken once daily, with clinical effects typically noticeable within 2 weeks
- The most common side effects are gastrointestinal symptoms such as burping with lavender taste and mild nausea, which are generally transient
- Not recommended during pregnancy or breastfeeding due to insufficient safety data; not approved for use in children under 18
What Is Lasea and What Is It Used For?
Lasea is a phytotherapeutic (plant-based) medicine developed by Dr. Willmar Schwabe GmbH & Co. KG in Germany. Its active ingredient, Silexan, is a proprietary essential oil preparation obtained through steam distillation of the flowering tops of Lavandula angustifolia (English lavender or narrow-leaved lavender). Silexan is standardized to contain specific quantities of the key active compounds linalool (25–38%) and linalyl acetate (25–45%), ensuring batch-to-batch consistency and reproducible clinical effects.
The primary approved indication for Lasea is the treatment of anxiety disorders, particularly generalized anxiety disorder (GAD) and subsyndromal anxiety – a condition where patients experience significant anxiety symptoms that do not fully meet the diagnostic criteria for a formal anxiety disorder but still substantially impair quality of life. Subsyndromal anxiety is estimated to affect up to 13% of the adult population and is associated with increased healthcare utilization, reduced work productivity, and elevated risk of developing full-threshold anxiety or depressive disorders.
Lasea has also demonstrated efficacy for anxiety-related sleep disturbances. In clinical trials, patients taking Silexan experienced significant improvements in both sleep quality and sleep duration alongside reductions in anxiety. This dual benefit is particularly valuable because anxiety and sleep disturbance frequently co-occur and exacerbate each other. Importantly, unlike sedative-hypnotic medications, Lasea improves sleep indirectly through anxiety reduction rather than through direct sedation, meaning it does not impair daytime alertness or cognitive function.
The European Medicines Agency (EMA) has assessed Lavandula angustifolia essential oil and published a Community herbal monograph recognizing its traditional and well-established use for anxiety and restlessness. In multiple European countries, Lasea is registered as an approved herbal medicinal product based on well-established use with demonstrated clinical efficacy. It is available in over 15 countries worldwide, including Germany, Austria, Sweden, and Australia.
Mechanism of Action
Silexan exerts its anxiolytic effects through a unique multi-target pharmacological mechanism that is fundamentally different from conventional anxiolytics such as benzodiazepines or selective serotonin reuptake inhibitors (SSRIs). The primary mechanism involves inhibition of voltage-dependent calcium channels (VDCCs), particularly the P/Q-type and N-type channels in presynaptic nerve terminals. By reducing calcium influx into neurons, Silexan decreases the release of excitatory neurotransmitters, thereby dampening excessive neuronal excitability associated with anxiety states.
Additionally, Silexan modulates serotonergic neurotransmission through partial agonism at 5-HT1A receptors and has been shown to reduce binding of the N-methyl-D-aspartate (NMDA) receptor agonist ifenprodil, suggesting an NMDA receptor modulatory effect. These combined mechanisms produce a broad-spectrum anxiolytic effect without the sedation, cognitive impairment, or muscle relaxation characteristic of GABAergic drugs. Crucially, because Silexan does not bind to GABA-A receptors, it carries no risk of physical dependence, tolerance development, or withdrawal symptoms upon discontinuation.
What Should You Know Before Taking Lasea?
While Lasea has a favorable safety profile compared to conventional anxiolytics, there are important considerations to be aware of before starting treatment. As with any medication, a thorough understanding of contraindications, warnings, and potential interactions is essential for safe use. The following sections outline the key precautions that patients and healthcare providers should consider.
Contraindications
Lasea should not be taken by individuals with a known hypersensitivity or allergy to lavender oil, linalool, linalyl acetate, or any of the excipients in the formulation. Although allergic reactions to orally administered lavender oil are rare, they can occur and may manifest as skin rash, itching, urticaria, or in very rare cases, more severe allergic reactions. Patients with a documented history of contact dermatitis to topical lavender preparations should exercise caution and discuss the risk with their healthcare provider before initiating oral Lasea therapy.
There are no absolute contraindications related to organ function, but patients with severe hepatic (liver) impairment should use Lasea with caution, as the metabolism of essential oil constituents may be affected. No dosage adjustments have been specifically studied in patients with renal impairment, but the primarily hepatic metabolism of Silexan suggests that renal impairment alone is unlikely to significantly alter drug exposure.
Warnings and Precautions
Patients should be advised that Lasea is not intended for acute anxiety relief. Unlike benzodiazepines, which provide rapid onset anxiolysis, Lasea requires consistent daily administration over at least 2 weeks before clinically meaningful effects become apparent, with full therapeutic benefit typically achieved after 4 to 6 weeks. Patients who require immediate relief from acute anxiety episodes should discuss alternative or adjunctive treatment options with their prescriber.
Lasea should be swallowed whole with sufficient liquid, ideally with a meal. The soft capsules should not be chewed, broken, or opened, as this may cause irritation of the oral mucosa and throat from direct contact with concentrated essential oil. If gastrointestinal symptoms such as burping with lavender taste or mild nausea occur, taking the capsule with food typically reduces these effects.
Lasea does not impair driving ability or the operation of machinery. Clinical studies have confirmed that Silexan 80 mg has no effect on psychomotor performance, reaction time, or cognitive function, making it suitable for patients who need to maintain full alertness during treatment.
Pregnancy and Breastfeeding
The safety of Lasea during pregnancy has not been established through adequate clinical studies. Animal reproductive toxicity studies with Silexan have not revealed evidence of teratogenicity or adverse effects on embryonic development at therapeutic doses, but human data are insufficient to rule out potential risks. As a precautionary measure, Lasea is not recommended during pregnancy, particularly during the first trimester, unless the expected benefit clearly outweighs the potential risk.
It is not known whether the active constituents of Silexan (primarily linalool and linalyl acetate) are excreted in human breast milk. Given the lipophilic nature of these essential oil components, passage into breast milk is theoretically possible. Therefore, use of Lasea during breastfeeding is not recommended. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider for alternative treatment options.
Children and Adolescents
Lasea is not approved for use in children and adolescents under 18 years of age. Clinical trials evaluating Silexan have been conducted exclusively in adult populations, and safety and efficacy data in pediatric patients are not available. The pharmacokinetics of essential oil constituents may differ significantly in children due to developmental differences in hepatic enzyme activity and body composition. Parents or caregivers seeking anxiety treatment for children or adolescents should consult a pediatrician or child psychiatrist for age-appropriate treatment options.
How Does Lasea Interact with Other Drugs?
Drug interaction studies with Silexan have been conducted using human liver microsomes and in clinical pharmacokinetic trials. These studies have demonstrated that Silexan does not significantly inhibit or induce the major cytochrome P450 (CYP) enzymes responsible for drug metabolism, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This favorable metabolic profile suggests a low likelihood of pharmacokinetic interactions with commonly prescribed medications that are metabolized through these enzyme pathways.
However, some pharmacodynamic interactions are theoretically possible based on the known pharmacological properties of Silexan. The following table summarizes the most clinically relevant potential interactions that healthcare providers and patients should be aware of.
Potential Drug Interactions
| Drug / Drug Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Benzodiazepines (e.g., lorazepam, diazepam) | Pharmacodynamic – additive CNS effects | Moderate | Use with caution; monitor for increased sedation |
| Anticoagulants (e.g., warfarin, heparin) | Theoretical – platelet aggregation effects | Low to Moderate | Monitor INR if used with warfarin |
| Sedative antihistamines (e.g., diphenhydramine) | Pharmacodynamic – additive sedation | Low | Be aware of potential drowsiness |
| Opioid analgesics | Pharmacodynamic – additive CNS depression | Moderate | Use with caution under medical supervision |
| SSRIs / SNRIs (e.g., sertraline, venlafaxine) | Pharmacodynamic – serotonergic modulation | Low | Generally safe; inform prescriber |
| Alcohol | Pharmacodynamic – additive CNS effects | Low | No formal interaction, but moderate alcohol use advised |
Interaction with CYP450 Enzymes
In vitro studies using human liver microsomes have demonstrated that Silexan at concentrations exceeding clinical exposure levels does not significantly inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Furthermore, Silexan did not induce CYP1A2 or CYP3A4 expression in human hepatocyte cultures. These findings indicate that pharmacokinetic drug interactions mediated through cytochrome P450 enzyme inhibition or induction are unlikely at the recommended therapeutic dose of 80 mg daily.
Despite this favorable metabolic profile, patients taking multiple medications should always inform their healthcare provider about Lasea use. This is particularly important for patients on narrow therapeutic index drugs such as warfarin, lithium, or digoxin, where even minor pharmacodynamic interactions could have clinical consequences.
What Is the Correct Dosage of Lasea?
The dosage of Lasea has been established through multiple dose-finding and confirmatory clinical trials. The recommended dosage is straightforward and does not require complex titration schedules, which contributes to good patient compliance. The following information provides detailed guidance on dosing for different patient populations.
Adults
Standard Adult Dosage
One soft capsule (80 mg Silexan) taken orally once daily. The capsule should be swallowed whole with a sufficient amount of liquid (at least 150 ml), preferably with a meal. Taking Lasea with food reduces the incidence of gastrointestinal side effects, particularly eructation (burping) with lavender taste.
Clinical trials have demonstrated efficacy with the 80 mg daily dose. A higher dose of 160 mg daily has also been studied and shown to provide greater anxiolytic effects in some patient populations, particularly those with more severe anxiety. However, the 80 mg dose is the standard recommended starting dose for most patients.
Duration of Treatment
The optimal duration of Lasea treatment depends on the clinical indication and individual patient response. In clinical trials evaluating Silexan for generalized anxiety disorder, treatment periods of 6 to 10 weeks have been studied with consistent demonstration of efficacy. The onset of therapeutic effect typically occurs within the first 2 weeks, with progressive improvement over the subsequent 4 to 8 weeks.
For patients with chronic or recurrent anxiety, longer-term treatment may be appropriate. Unlike benzodiazepines, there is no evidence that Lasea loses efficacy over time (tolerance) or that prolonged use creates physical dependence. However, periodic reassessment by a healthcare provider is recommended to evaluate ongoing treatment necessity and response.
Elderly Patients
No dosage adjustment is required for elderly patients. Clinical trials included patients up to 75 years of age, and no age-related differences in efficacy or safety were observed. Elderly patients metabolize Silexan at rates comparable to younger adults, and the absence of sedative effects makes Lasea particularly suitable for older patients who are at increased risk of falls associated with benzodiazepine use.
Missed Dose
If a dose of Lasea is missed, patients should take it as soon as they remember on the same day. If it is close to the time of the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to compensate for a missed one. Because Lasea works through gradual modulation of neuronal excitability rather than acute receptor binding, missing a single dose is unlikely to cause rebound anxiety or other adverse effects.
Overdose
There are no reports of serious adverse events following acute overdose with Silexan in clinical studies. In dose-escalation studies, doses up to 160 mg daily were administered without significant safety concerns. Based on the pharmacological profile of Silexan, symptoms of substantial overdose might theoretically include gastrointestinal discomfort, nausea, and potentially mild sedation.
If a significant overdose is suspected, contact your local poison control center or seek immediate medical attention. Treatment is symptomatic and supportive, as no specific antidote exists. While serious toxicity from Lasea overdose is considered unlikely, medical evaluation is recommended for any ingestion substantially exceeding the prescribed dose.
Dosage Summary Table
| Patient Group | Dosage | Frequency | Notes |
|---|---|---|---|
| Adults (18–65 years) | 80 mg (1 capsule) | Once daily | Swallow whole with water; take with food |
| Elderly (>65 years) | 80 mg (1 capsule) | Once daily | No dose adjustment needed |
| Children (<18 years) | Not recommended | N/A | Safety and efficacy not established |
| Hepatic impairment (mild) | 80 mg (1 capsule) | Once daily | Use with caution; monitor tolerability |
| Renal impairment | 80 mg (1 capsule) | Once daily | No adjustment expected to be necessary |
What Are the Side Effects of Lasea?
Lasea has been evaluated for safety across multiple randomized controlled trials involving over 2,600 patients. The overall safety profile is favorable, with the majority of adverse events being mild to moderate in severity and gastrointestinal in nature. Importantly, clinical studies have consistently demonstrated that Lasea does not cause the sedation, psychomotor impairment, dependence, or withdrawal effects that are characteristic of benzodiazepines and other conventional anxiolytics.
The following side effect frequency grid categorizes adverse reactions based on data from pooled clinical trial analyses, using the standard frequency classification system recommended by the Council for International Organizations of Medical Sciences (CIOMS).
Common
- Eructation (burping) with lavender taste or smell
- Nausea
- Dyspepsia (indigestion)
Uncommon
- Abdominal pain
- Diarrhea
- Flatulence
- Dry mouth
- Headache
- Allergic skin reactions (rash, pruritus)
Rare
- Hypersensitivity reactions
- Contact dermatitis (in predisposed individuals)
- Dysgeusia (taste disturbance)
- Vomiting
Gastrointestinal Side Effects
The most frequently reported side effect of Lasea is eructation (burping) with a characteristic lavender taste or aroma. This occurs because the soft capsule dissolves in the stomach, releasing the essential oil, which can reflux into the esophagus. In clinical trials, this side effect occurred in approximately 3–6% of patients, though it was rarely reported as bothersome enough to cause treatment discontinuation. Taking the capsule with a meal significantly reduces the incidence and severity of this effect.
Nausea and dyspepsia have been reported in approximately 2–4% of patients. These gastrointestinal effects are typically mild, transient, and tend to diminish with continued treatment. In pooled safety analyses, the rate of treatment discontinuation due to gastrointestinal adverse events was less than 1%, comparable to placebo groups.
Absence of Central Nervous System Side Effects
One of the most clinically significant safety advantages of Lasea is the absence of the central nervous system (CNS) side effects commonly associated with conventional anxiolytics. Specifically, Lasea does not cause sedation or drowsiness, impaired concentration or memory, psychomotor retardation, dizziness related to CNS depression, or muscle weakness or fatigue. Multiple studies using validated psychometric tests, including the d2 attention test and the Vienna Test System, have confirmed that Silexan 80 mg has no adverse effects on attention, reaction time, or driving-related cognitive functions.
No Dependence or Withdrawal
Perhaps the most important safety feature of Lasea is the complete absence of dependence potential. Because Silexan does not interact with GABA-A receptors, the molecular targets responsible for benzodiazepine dependence, there is no pharmacological basis for tolerance, physical dependence, or withdrawal upon discontinuation. Clinical studies of up to 10 weeks duration with subsequent abrupt discontinuation have confirmed no rebound anxiety, withdrawal symptoms, or other signs of physical dependence. This makes Lasea particularly suitable for patients who have concerns about benzodiazepine dependence or who have a history of substance use disorders.
While serious side effects from Lasea are rare, you should contact your healthcare provider if you experience severe abdominal pain, persistent vomiting, signs of allergic reaction (widespread rash, swelling of the face or throat, difficulty breathing), or any symptoms that concern you. If you experience a severe allergic reaction, seek immediate medical attention.
How Should You Store Lasea?
Proper storage of Lasea is important to maintain the stability and efficacy of the Silexan essential oil formulation. As a soft gelatin capsule containing a volatile essential oil preparation, Lasea is more sensitive to environmental conditions than conventional solid dosage forms. The following storage guidelines should be observed to ensure the product retains its quality throughout its shelf life.
Store the capsules at room temperature, ideally between 15°C and 25°C (59°F to 77°F). Avoid exposure to temperatures above 30°C (86°F), as excessive heat can cause the soft gelatin capsule shell to soften, stick together, or deform. Similarly, avoid storing in excessively cold conditions such as a freezer, as this may affect the capsule shell integrity.
Keep the capsules in the original blister packaging until immediately before use. This protects them from exposure to light and atmospheric moisture, both of which can degrade the essential oil constituents and reduce efficacy. Once removed from the blister, capsules should be taken promptly. Do not store loose capsules in pill organizers for extended periods.
As with all medicines, keep Lasea out of the reach and sight of children. Do not use the product after the expiry date stated on the carton and blister strip. The expiry date refers to the last day of that month. Do not dispose of medications through household waste or wastewater; ask your pharmacist about proper disposal methods for unused or expired medications to protect the environment.
What Does Lasea Contain?
Active Ingredient
The active ingredient in Lasea is Silexan, a proprietary standardized preparation of essential oil obtained by steam distillation from the flowering tops of Lavandula angustifolia Miller (synonyms: Lavandula officinalis, Lavandula vera). Each soft capsule contains 80 mg of this essential oil. Silexan is standardized to contain 25–38% linalool and 25–45% linalyl acetate, the two principal bioactive monoterpenoids responsible for the anxiolytic effects. The oil also contains smaller quantities of other terpenes including terpinen-4-ol, lavandulol, lavandulyl acetate, 1,8-cineole, and camphor.
Inactive Ingredients (Excipients)
The soft capsule formulation contains several inactive ingredients necessary for the manufacturing process, capsule shell formation, and stability of the product. These excipients include:
- Medium-chain triglycerides (MCT oil) – used as a lipophilic carrier for the essential oil in the capsule fill
- Gelatin – forms the outer soft capsule shell
- Glycerol (85%) – plasticizer for the gelatin shell, maintaining flexibility
- Sorbitol liquid (non-crystallizing) – additional plasticizer and sweetener
- Titanium dioxide (E171) – white colorant for the capsule shell (in some formulations)
- Indigo carmine (E132) – blue colorant (in some formulations)
- Purified water – used in the capsule shell manufacturing process
The exact excipient composition may vary slightly between different market formulations and manufacturing batches. Patients with known allergies or intolerances to any of these ingredients, particularly gelatin (derived from animal sources) or specific colorants, should review the full list of excipients on the product packaging or consult their pharmacist before use. Lasea soft capsules are not suitable for vegetarians or vegans due to the gelatin capsule shell.
Frequently Asked Questions About Lasea
Lasea is a herbal medicine containing Silexan, a standardized lavender oil extract from Lavandula angustifolia. It is primarily used to treat anxiety disorders, subsyndromal anxiety, and restlessness in adults. Clinical trials have demonstrated its efficacy in generalized anxiety disorder (GAD), subsyndromal anxiety, and anxiety-related sleep disturbances. Unlike benzodiazepines, Lasea does not cause sedation, dependence, or withdrawal symptoms.
Lasea's active ingredient Silexan works by inhibiting voltage-dependent calcium channels (VDCC) in the central nervous system, reducing excessive neuronal excitability. It also modulates serotonin 5-HT1A receptors and has NMDA receptor inhibitory properties. This multi-target mechanism produces anxiolytic effects comparable to lorazepam in clinical studies, without the sedation or addiction potential of benzodiazepines.
No, Lasea is not addictive. Unlike benzodiazepines and other conventional anxiolytics, Lasea does not interact with GABA-A receptors and therefore carries no risk of physical dependence or withdrawal symptoms. Multiple clinical trials lasting up to 10 weeks have confirmed no rebound anxiety or withdrawal effects upon discontinuation. This is one of the key advantages of Lasea for long-term anxiety management.
Lasea has a favorable drug interaction profile, but some caution is warranted. It may enhance the effects of sedative medications such as benzodiazepines, antihistamines, and opioids. There is a theoretical interaction with anticoagulants like warfarin, as lavender oil may affect platelet aggregation. Always consult your doctor or pharmacist before combining Lasea with other medications, particularly sedatives, blood thinners, or other CNS-active drugs.
Clinical studies show that Lasea begins to reduce anxiety symptoms within the first two weeks of treatment. However, the full therapeutic effect typically develops over 4 to 6 weeks of consistent daily use. Unlike benzodiazepines, Lasea does not provide immediate acute anxiolytic relief. Patients should take Lasea regularly as prescribed and not use it as an on-demand anxiety treatment.
Clinical studies have not shown a significant interaction between Lasea and alcohol. Unlike benzodiazepines, Lasea does not potentiate the sedative effects of alcohol in a clinically meaningful way. However, moderate alcohol consumption is generally advised during any anxiety treatment, as alcohol itself can worsen anxiety symptoms and interfere with recovery. Always discuss alcohol use with your healthcare provider.
References & Medical Sources
This article is based on peer-reviewed medical literature, international clinical guidelines, and regulatory assessments. All claims are supported by Level 1A evidence where available.
- Kasper S, Gastpar M, Müller WE, et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo-controlled trial. International Clinical Psychopharmacology. 2010;25(5):277–287. doi:10.1097/YIC.0b013e32833b3f71
- Kasper S, Gastpar M, Müller WE, et al. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wiener Medizinische Wochenschrift. 2010;160(21–22):547–556. doi:10.1007/s10354-010-0845-7
- Kasper S, Anghelescu I, Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – a randomized, placebo-controlled trial. European Neuropsychopharmacology. 2015;25(11):1960–1967. doi:10.1016/j.euroneuro.2015.07.024
- Kasper S, Volz HP, Dienel A, Schläfke S. Efficacy of Silexan in mixed anxiety-depression – a randomized, placebo-controlled trial. European Neuropsychopharmacology. 2016;26(2):331–340. doi:10.1016/j.euroneuro.2015.12.002
- Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94–99. doi:10.1016/j.phymed.2009.10.006
- European Medicines Agency (EMA). Community herbal monograph on Lavandula angustifolia Miller, aetheroleum. EMA/HMPC/143183/2010. 2012.
- Schuwald AM, Noldner M, Wilmes T, et al. Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One. 2013;8(4):e59998. doi:10.1371/journal.pone.0059998
- Müller WE, Sillani G, Schuwald A, Noldner M. Pharmacological basis of the anxiolytic and antidepressant properties of Silexan, an essential oil from the flowers of lavender. Neurochemistry International. 2021;143:104899. doi:10.1016/j.neuint.2020.104899
- World Health Organization (WHO). WHO monographs on selected medicinal plants. Volume 3. Geneva: World Health Organization; 2007.
- Generoso MB, Soares A, Taiar IT, Cordeiro Q, Shiozawa P. Lavender oil preparation (Silexan) for treating anxiety: an updated meta-analysis. Journal of Clinical Psychopharmacology. 2017;37(1):115–117. doi:10.1097/JCP.0000000000000615
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in psychiatry, pharmacology, and phytotherapy.
iMedic Medical Editorial Team – specialists in psychiatry, pharmacology, and evidence-based phytotherapy with documented academic background and clinical experience.
iMedic Medical Review Board – independent panel of medical experts who review all content according to international guidelines (EMA, WHO, NICE).
All medical content on iMedic follows the GRADE evidence framework and is based on systematic reviews, meta-analyses, and randomized controlled trials where available. Content is updated regularly to reflect the latest clinical evidence and guideline revisions. We maintain complete editorial independence with no commercial funding or pharmaceutical sponsorship. Read our full editorial policy.